GLP-1 receptor agonist medications — Novo Nordisk’s Ozempic and Wegovy, Eli Lilly’s Mounjaro and Zepbound — have rewritten the rules of metabolic medicine. They’ve also, unexpectedly, started rewriting balance sheets in the fashion and retail industry.
This week, shares of Fast Retailing (TYO: 9983), the Japanese conglomerate behind the Uniqlo brand, surged to a record high after the company raised its full-year profit forecast, citing broad-based strength in comparable store sales across North America, Europe, and Asia. While Uniqlo’s success reflects multiple factors — lean inventory management, affordable-basics positioning, and global brand expansion — several analysts noted an emerging tailwind: a measurable uptick in consumers refreshing their wardrobes after significant weight changes.
Welcome to what Wall Street is starting to call the Ozempic Effect.
A New Wardrobe Boom Takes Shape
As of early 2025, an estimated 15 to 20 million Americans were taking some form of GLP-1 medication. Goldman Sachs, in a widely cited 2024 research note, projected that number could rise to 30 million by 2030 — roughly 9% of the U.S. adult population. That projection has since been revised upward as insurance coverage has expanded and newer, more accessible formulations have entered the market.
The average GLP-1 user on semaglutide (Ozempic’s active ingredient) loses between 15% and 20% of their body weight over 68 weeks of treatment, according to clinical trial data published in the New England Journal of Medicine. For tirzepatide (Mounjaro/Zepbound), that figure climbs to 22.5%. These are not incremental losses — they are body-transforming events that render most of a person’s existing wardrobe unwearable.
Jeans, suits, dresses, athletic gear: all of it needs replacing. A 2024 consumer survey found that approximately 65% of significant GLP-1 users — those who lost at least 20 pounds — reported purchasing new clothing within six months. That purchasing cycle represents a spending event that retailers are only beginning to fully quantify.
Which Retail Stocks Are Gaining a GLP-1 Tailwind
Athletic and Active Wear: The Clear Winner
No segment has benefited more from the GLP-1 wave than performance and active wear. As users shed weight, many become more physically active — and increasingly conscious of their appearance. Brands that cater to the newly athletic or newly body-confident are seeing disproportionate demand.
Lululemon Athletica (LULU) has been one of the highest-profile potential beneficiaries. On its most recent earnings call, executives noted that “the active customer is getting younger, and she’s showing up more often.” Industry analysts at Bernstein Research went further, explicitly stating that “the GLP-1 cohort represents an incremental customer for performance apparel,” particularly in the 35-to-55 age bracket — the demographic most likely to be prescribed weight-loss medications.
Nike (NKE) and Under Armour (UA), while navigating separate inventory and market-share headwinds, have also flagged GLP-1 adoption as a potential demand driver in their consumer trend discussions. Nike’s North American performance segment, which had been under pressure through much of 2024, has shown stabilizing demand partly attributed to a broader wellness boom that GLP-1 adoption is helping accelerate.
Fast Fashion and Value Players: Wardrobe Refresh Central
When people need to replace their wardrobe rapidly, they don’t always reach for premium labels. For many GLP-1 users — particularly those still in the active weight-loss phase — value-oriented, accessible brands like Uniqlo, H&M, Zara, and Old Navy have been the first port of call. The logic is practical: if you expect to lose more weight, you don’t want to drop $300 on a blazer yet.
That’s precisely why Fast Retailing, Uniqlo’s parent, is well-positioned to capture early-cycle GLP-1 spending. Their core proposition — high-quality basics at accessible price points — is a near-perfect fit for the wardrobe-rebuilding shopper. Shares of Fast Retailing have gained approximately 28% over the past 12 months in yen terms, a performance that reflects both the company’s execution and structural tailwinds the market is only now beginning to price in.
H&M Group (HM-B.ST) and Inditex — parent of Zara — have both seen similar dynamics in their most recent quarterly results, with North American and European traffic outperforming internal expectations. Inditex’s comparable-store sales figures, which came in above Wall Street consensus estimates in its latest report, reflect in part this emerging demand source.
Department Stores: A More Complicated Picture
Traditional department stores like Macy’s (M), Nordstrom (JWN), and Kohl’s (KSS) face a more nuanced GLP-1 dynamic. On one hand, a customer replacing their entire wardrobe in a concentrated window is a high-ticket event that drives traffic and basket sizes. On the other hand, many legacy department stores carry heavily indexed plus-size clothing assortments, and that segment faces structural demand softening as GLP-1 adoption accelerates.
Specialty plus-size retailers have already flagged weakening comparable-store sales. Analysts at Wells Fargo noted in early 2026 that the plus-size apparel market — one of retail’s few consistent growth categories through the 2010s — may be entering a cyclical downturn tied in part to GLP-1 adoption, though inventory and broader consumer confidence trends are also contributing factors.
The Scale of the Opportunity
The financial community is beginning to assign numbers to the GLP-1 retail tailwind. Morgan Stanley estimated in a 2025 research note that weight-loss-driven apparel spending could generate $3 billion to $5 billion in incremental annual retail sales in the United States by 2027, as the user base grows and initial wardrobe replacements give way to recurring purchases of higher-quality items.
Critically, this isn’t a one-time spending burst. As more Americans reach maintenance doses and sustain their weight loss long-term, the behavioral shift — more exercise, more social activity, more wardrobe investment — becomes self-reinforcing. The spending thesis evolves from “wardrobe refresh” to “lifestyle upgrade,” a far more durable demand driver.
Analysts note that the GLP-1 demographic skews toward higher-income households — at least at the current stage, when medications remain expensive and insurance coverage is still expanding. That income skew means the incremental retail spending is more likely to flow toward premium and mid-market brands rather than deep discounters, improving the margin profile of the opportunity.
The Counterweight: Not All Retailers Are Celebrating
The GLP-1 era creates losers alongside winners. Food and snack manufacturers have already felt the pinch; companies like Hershey (HSY) and Conagra Brands (CAG) have cited softening volume growth in their snack and indulgent food segments. For apparel, the clearest negative is in the plus-size category, but there are broader considerations too.
Consumers who spend $900 to $1,200 per month on GLP-1 medications — still a realistic out-of-pocket cost for patients without comprehensive insurance coverage — have meaningfully less discretionary income for other categories, including clothing. The net spending effect for any individual retailer depends heavily on which consumer cohort they serve and how insurance coverage continues to evolve.
Additionally, if GLP-1 adoption plateaus or if new clinical data introduces doubts about long-term safety or efficacy, the tailwind could moderate more quickly than current projections suggest. It remains an emerging, rather than established, structural trend.
What Investors Are Watching This Earnings Season
With Q1 2026 earnings season now underway, retail executives’ commentary on GLP-1 trends will be closely scrutinized. The key questions analysts are posing include: How durable is the wardrobe rebuild cycle — is it front-loaded, or spread over multiple seasons? Which size ranges are showing the strongest demand? And are GLP-1 users trading up in quality over time, benefiting premium brands, or staying at value retailers?
Fast Retailing’s record-high share price this week may be an early signal that the market is finally beginning to connect the GLP-1 adoption curve to retail sector fundamentals. Whether other global apparel names follow will depend on what their next earnings calls reveal — and on how rapidly analysts update their models to reflect a behavioral shift that, until recently, barely appeared on Wall Street’s radar.
Disclosure: This article was produced with AI assistance and reviewed before publication. It is for informational purposes only and is not investment advice.